Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473251 · ClinicalTrials.gov registry record · NA
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
A NA study, sponsored by Vitreo-Retinal Associates, Michigan.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01473251 is a NA study that has completed, run by Vitreo-Retinal Associates, Michigan. The registered enrollment target is 16 participants.
The verdict
NCT01473251, a NA study, has completed, sponsored by Vitreo-Retinal Associates, Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
Interventions
- DRUG Avastin
- DRUG Lucentis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473251
The ClinicalTrials.gov registry entry for NCT01473251 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vitreo-Retinal Associates, Michigan, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avastin is the first listed.
NCT01473251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473251 about?
NCT01473251 is a clinical study titled "Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration". The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
What is the current status of trial NCT01473251?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2011-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01473251?
The interventions under investigation include: Avastin (DRUG), Lucentis (DRUG).
Who is sponsoring clinical trial NCT01473251?
This trial is sponsored by Vitreo-Retinal Associates, Michigan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.